Cutting Through Complexity: The Promise Of Biomarkers To Discover, Diagnose, And Treat Antibody-associated Demyelination
Funder
National Health and Medical Research Council
Funding Amount
$438,768.00
Summary
Patients with damage to myelin, the sheath around nerve cells in the brain, have “demyelinating disorders” which can result in severe disability including blindness and paralysis. In some patients, their immune system mistakenly targets certain proteins in the brain. This research project will identify new targets in currently undiagnosed patients, increase our understanding of underlying disease processes, and evaluate optimal treatment strategies in these patients to improve their outcomes.
Development Of A Magnetic Resonance Imaging (MRI) Platform To Evaluate Neuroprotective And Regenerative Therapies In MS
Funder
National Health and Medical Research Council
Funding Amount
$116,667.00
Summary
Multiple Sclerosis (MS) involves inflammation and damage to nerve cells. New therapies are needed to minimize and reverse nerve cell damage. Currently, ways to judge the benefit of these therapies are primitive. We propose that assessing the benefits of these treatments in optic neuritis (inflammation of the eye nerve) is the way forward but first, we need to develop reliable tests to measure these treatments. This application proposes to use magnetic resonance imaging (MRI) for this purpose.
Assessing Paraclinical Measures Of Axonal Degeneration Following Acute Optic Neuritis
Funder
National Health and Medical Research Council
Funding Amount
$367,450.00
Summary
Multiple Sclerosis (MS) is caused by immune attack on the central nervous system (CNS), resulting in loss of the insulating material that surrounds nerve cells, as well as a degree of loss of the nerve cells themselves. Several partially effective therapies are available. A hurdle in developing CNS based therapies is methods to adequately test them. This study aims to assess biomarkers that could potentially be used to measure the damage in the optic nerve, a commonly affected structure in MS.
Investigating Trans-synaptic Degeneration In The Human Visual Pathway
Funder
National Health and Medical Research Council
Funding Amount
$79,514.00
Summary
This research project investigates the spread of neuronal damage along the visual pathway from the retina to higher order areas including the visual cortex and inter-hemispheric tracts. This trans-synaptic degeneration will be examined in Leber's optic atrophy, optic neuritis and glaucoma.
Investigating The Neural Mechanisms Of Visual Recovery After Acute Optic Neuritis
Funder
National Health and Medical Research Council
Funding Amount
$311,860.00
Summary
Patients with multiple sclerosis experience relapses followed by disease remission. Recently, neuroplasticity, or the brain's innate ability to reorganise itself to maintain function after injury, has been thought to play a significant role in remission. We study patients with optic neuritis, which causes loss of vision, to understand visual parts of the brain change during recovery to enable patients to see again despite ongoing brain injury.
Oxidative Phosphorylation Regulation And Neuroprotection In Optic Neuropathies
Funder
National Health and Medical Research Council
Funding Amount
$430,231.00
Summary
We have shown clear differences in the mitochodria, cellular organelles that generate energy, between optic atrophy patients who have good vision and those of patients who have poor vision. We believe that these changes represent a compensation mechanisms that preserves mitochondrial energy production and protects optic nerve cells. This study will characterize these differences further with the aim of identfying new treatments for preventing nerve loss and preserving vision.
Genetic Determinants Of Inherited Optic Neuropathies
Funder
National Health and Medical Research Council
Funding Amount
$249,750.00
Summary
Glaucoma is a slowly progressive visual disorder of the optic nerves often but not always associated with elevated pressure in the eyes. There is a strong genetic component. It is estimated to affect in excess of 60 million people worldwide with more than 6 million of those blind in both eyes. It is the second commonest cause of visual impairment in the developed world, and is present in up to 10% of the population by age 90. Numbers of affected patients in Australia are expected to double in th ....Glaucoma is a slowly progressive visual disorder of the optic nerves often but not always associated with elevated pressure in the eyes. There is a strong genetic component. It is estimated to affect in excess of 60 million people worldwide with more than 6 million of those blind in both eyes. It is the second commonest cause of visual impairment in the developed world, and is present in up to 10% of the population by age 90. Numbers of affected patients in Australia are expected to double in the next 30 years. Current methods of early detection and treatment are often inadequate, and associated visual loss is irreversible. There is a strong need for greater understanding of the disease process and new strategies to prevent and treat visual loss. Two less common causes of untreatable optic nerve blindness are Leber Hereditary Optic Neuropathy (LHON) and autosomal dominant optic atrophy (ADOA) which occur in younger age groups than most cases of glaucoma, and hence sufferers may experience substantial physical, emotional and economic hardship. Over a 10 year period we have seen large numbers of patients with all three eye conditions and have developed a powerful study to determine the genes which cause optic nerve blindness and their relative importance. The research is gathering momentum and the genetics of all 3 conditions are now partly understood. This project seeks to analyse a new major glaucoma gene (Optineurin) in our Australian population and to try to understand the way in which a number of genes interact to cause blindness in some patients but not others. This work will lead to greater understanding of these causes of blindness and is likely to lead to new screening tests to know who is at most risk, and the opportunity to develop and test new treatments targeted to the underlying genetic problem.Read moreRead less
OXPHOS Upregulation To Preserve Vision In Leber's Hereditary Optic Neuropathy
Funder
National Health and Medical Research Council
Funding Amount
$496,874.00
Summary
Leber's Hereditary Optic Neuropathy (LHON) is a devastating blinding disease that preferentially affects young men. Sufferers have normal vision until teenage years or their twenties when a rapid loss of vision occurs that results in permanent blindness. It is caused by genetic changes in the mitochondrial DNA that we inherit from our mothers. The mitochondria are the cells' energy generators. We aim to use molecules similar to female hormones to boost energy as a new treatment to preserve visio ....Leber's Hereditary Optic Neuropathy (LHON) is a devastating blinding disease that preferentially affects young men. Sufferers have normal vision until teenage years or their twenties when a rapid loss of vision occurs that results in permanent blindness. It is caused by genetic changes in the mitochondrial DNA that we inherit from our mothers. The mitochondria are the cells' energy generators. We aim to use molecules similar to female hormones to boost energy as a new treatment to preserve vision in at-risk LHON individuals.Read moreRead less
Ictal Characteristics Of Common Vestibular Diseases
Funder
National Health and Medical Research Council
Funding Amount
$281,573.00
Summary
vertigo is a disabling symptom affecting 1 million Australians at any given time. Acute vertigo is associated with abnormal eye movements or nystagmus, the pattern of which points to its origin. In this project, we extract the unique characteristics of distinct vertigo syndromes to enable their separation